This article is more than 5 years old. Information may no longer be current.

Samsung Bioepis, Takeda collaborate on severe pancreatitis therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Samsung Bioepis has joined with Takeda to develop multiple novel biologic therapies, including the collaboration’s first therapeutic candidate, TAK-671 for severe acute pancreatitis, according to a press release.

“Takeda’s extensive knowledge and expertise in drug development makes the company an ideal partner for us as we open a new chapter at Samsung Bioepis,” Christopher Hansung Ko, president and CEO of Samsung Bioepis, said in the release. “Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.”

Takeda’s head of the center for external innovation, Daniel Curran, MD, also commented saying, “At Takeda, we think differently — and creatively — about what makes a partnership successful and look to build on our strengths by collaborating with partners who have complementary expertise.”

Additional terms of the collaboration have not been disclosed yet.

Reference: www.samsungbioepis.com